• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对印度生产的鼠脑灭活日本脑炎疫苗有效性的评估。

Evaluation of effectiveness of mouse brain inactivated Japanese encephalitis vaccine produced in India.

作者信息

Gowal D, Tahlan A K

机构信息

Japanese Encephalitis Vaccine Division, Central Research Institute, Kasauli.

出版信息

Indian J Med Res. 1995 Dec;102:267-71.

PMID:8557319
Abstract

Efficacy of mouse brain inactivated Japanese encephalitis vaccine was evaluated by studying the immune status of volunteers 1,2,3,4.5 and 7.5 yr after immunization. Neutralizing (N) antibody which is protective and found to correlate with the immunity after vaccination was estimated in serum by plaque reduction neutralizing test on chick embryo cell monolayer. Mean N-antibody titres of 3.25 (pre-booster) and 3.6, 2.8, 2.06, 1.85 and 1.50 log10 were observed post-booster, and 1,2,3, and 4.5 yr of immunization in volunteers who received complete immunization (3 doses). All the volunteers retained more than 1.0 log10 titre of protective N-antibody in spite of the loss of 0.8, 0.74, 0.21 and 0.35 log10 after 1,2,3, and 4.5 yr respectively. Similarly mean N-antibody titres of 1.6, 3.25, 2.4, 2.25, 1.92 and 1.60 log10 were observed pre-booster, after a single booster dose, and 1,2,3 and 4.5 yr of vaccination in individuals who received only a single booster dose. Ten serum samples of volunteers tested after 7.5 yr of vaccination showed that those who were in constant contact with JE virus (n = 7) in the laboratory maintained high levels of N-antibody whereas others (n = 3) showed a fall in titre indicating the necessity of a booster dose.

摘要

通过研究志愿者免疫后1年、2年、3年、4.5年、5年和7.5年的免疫状态,评估了鼠脑灭活乙型脑炎疫苗的效力。通过在鸡胚细胞单层上进行蚀斑减少中和试验,估计血清中具有保护作用且发现与疫苗接种后免疫力相关的中和(N)抗体。在接受全程免疫(3剂)的志愿者中,加强免疫后以及免疫后1年、2年、3年和4.5年观察到的平均N抗体滴度分别为3.25(加强免疫前)和3.6、2.8、2.06、1.85和1.50 log10。尽管在1年、2年、3年和4.5年后分别下降了0.8、0.74、0.21和0.35 log10,但所有志愿者仍保持超过1.0 log10滴度的保护性N抗体。同样,在仅接受一次加强免疫的个体中,加强免疫前、单次加强免疫后以及接种疫苗后1年、2年、3年和4.5年观察到的平均N抗体滴度分别为1.6、3.25、2.4、2.25、1.92和1.60 log10。接种疫苗7.5年后检测的10份志愿者血清样本显示,那些在实验室中经常接触乙脑病毒的人(n = 7)保持较高水平的N抗体,而其他人(n = 3)滴度下降,表明需要加强免疫。

相似文献

1
Evaluation of effectiveness of mouse brain inactivated Japanese encephalitis vaccine produced in India.对印度生产的鼠脑灭活日本脑炎疫苗有效性的评估。
Indian J Med Res. 1995 Dec;102:267-71.
2
Immune status of volunteers one year after administration of Japanese encephalitis vaccine produced in India.接种印度生产的日本脑炎疫苗一年后志愿者的免疫状况。
Indian J Med Res. 1989 Nov;89:362-7.
3
Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.初免和加强免疫接种乙型脑炎疫苗的交叉保护作用:一项为期两年的随访研究。
Vaccine. 2013 Dec 17;32(1):119-23. doi: 10.1016/j.vaccine.2013.10.055. Epub 2013 Oct 28.
4
Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.嵌合型减毒活乙型脑炎疫苗(ChimeriVax-JE):安全性和免疫原性的2期临床试验、疫苗剂量和接种程序的效果以及对灭活乙型脑炎抗原攻击的记忆反应
J Infect Dis. 2003 Oct 15;188(8):1213-30. doi: 10.1086/378356. Epub 2003 Oct 3.
5
Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis.使用日本脑炎灭活疫苗加强免疫六年后抗体的持续性。
Vaccine. 2015 Jul 9;33(30):3600-4. doi: 10.1016/j.vaccine.2015.05.037. Epub 2015 May 30.
6
Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.初免一剂vero 细胞培养灭活流行性乙型脑炎疫苗(JE-VC)后的长期免疫原性,以及既往接种过鼠脑源灭活流行性乙型脑炎疫苗儿童再次接种JE-VC 疫苗的安全性和免疫原性。
Vaccine. 2018 Mar 7;36(11):1398-1404. doi: 10.1016/j.vaccine.2018.01.075.
7
Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine.一剂vero 细胞培养来源的日本脑炎(JE)疫苗在既往接种过鼠脑来源 JE 疫苗的成年人中的免疫原性。
Vaccine. 2012 Apr 26;30(20):3090-6. doi: 10.1016/j.vaccine.2012.02.063. Epub 2012 Mar 6.
8
Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains.当前灭活日本脑炎疫苗针对不同日本脑炎病毒株的免疫原性和保护效力
Vaccine. 2000 May 26;18 Suppl 2:33-5. doi: 10.1016/s0264-410x(00)00041-4.
9
Japanese encephalitis DNA vaccine candidates expressing premembrane and envelope genes induce virus-specific memory B cells and long-lasting antibodies in swine.表达前膜和包膜基因的日本脑炎DNA候选疫苗可在猪体内诱导病毒特异性记忆B细胞和持久抗体。
Virology. 2000 Mar 1;268(1):49-55. doi: 10.1006/viro.1999.0142.
10
Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers.抗日本脑炎病毒与 JE 疫苗(IXIARO(®))诱导的中和抗体效价的相关性。
Vaccine. 2011 Aug 11;29(35):5925-31. doi: 10.1016/j.vaccine.2011.06.062. Epub 2011 Jun 30.

引用本文的文献

1
Japanese Encephalitis Vaccines.日本脑炎疫苗
Curr Treat Options Infect Dis. 2020;12(4):375-386. doi: 10.1007/s40506-020-00242-5. Epub 2020 Nov 12.
2
Comparing the immunogenicity and safety of 3 Japanese encephalitis vaccines in Asia-Pacific area: A systematic review and meta-analysis.比较亚太地区3种日本脑炎疫苗的免疫原性和安全性:一项系统评价和荟萃分析。
Hum Vaccin Immunother. 2015;11(6):1418-25. doi: 10.1080/21645515.2015.1011996.
3
Development of a vaccine to prevent Japanese encephalitis: a brief review.开发预防日本脑炎的疫苗:简要回顾。
Int J Gen Med. 2009 Dec 29;2:195-200. doi: 10.2147/ijgm.s6281.
4
Vaccines for preventing Japanese encephalitis.预防日本脑炎的疫苗。
Cochrane Database Syst Rev. 2007 Jul 18;2007(3):CD004263. doi: 10.1002/14651858.CD004263.pub2.
5
Viral encephalitis of public health significance in India: current status.印度具有公共卫生意义的病毒性脑炎:现状
Indian J Pediatr. 1999 Jan-Feb;66(1):73-83. doi: 10.1007/BF02752357.